BEYOND AIR INC (XAIR)

US08862L1035 - Common Stock

0.36  +0 (+0.22%)

After market: 0.36 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XAIR. XAIR was compared to 187 industry peers in the Health Care Equipment & Supplies industry. XAIR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XAIR is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XAIR has reported negative net income.
In the past year XAIR has reported a negative cash flow from operations.
XAIR had negative earnings in each of the past 5 years.
In the past 5 years XAIR always reported negative operating cash flow.

1.2 Ratios

XAIR has a Return On Assets of -104.67%. This is amonst the worse of the industry: XAIR underperforms 83.33% of its industry peers.
XAIR's Return On Equity of -197.27% is on the low side compared to the rest of the industry. XAIR is outperformed by 76.34% of its industry peers.
Industry RankSector Rank
ROA -104.67%
ROE -197.27%
ROIC N/A
ROA(3y)-76.83%
ROA(5y)-72.3%
ROE(3y)-149.03%
ROE(5y)-127.06%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

XAIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

XAIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XAIR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XAIR has been increased compared to 5 years ago.
XAIR has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -9.11, we must say that XAIR is in the distress zone and has some risk of bankruptcy.
XAIR has a worse Altman-Z score (-9.11) than 80.11% of its industry peers.
XAIR has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
XAIR's Debt to Equity ratio of 0.39 is in line compared to the rest of the industry. XAIR outperforms 44.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z -9.11
ROIC/WACCN/A
WACC11.79%

2.3 Liquidity

A Current Ratio of 5.76 indicates that XAIR has no problem at all paying its short term obligations.
XAIR's Current ratio of 5.76 is amongst the best of the industry. XAIR outperforms 80.65% of its industry peers.
A Quick Ratio of 5.38 indicates that XAIR has no problem at all paying its short term obligations.
XAIR has a better Quick ratio (5.38) than 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 5.76
Quick Ratio 5.38

More info and screens

5

3. Growth

3.1 Past

XAIR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.55%, which is quite impressive.
XAIR shows a strong growth in Revenue. In the last year, the Revenue has grown by 680.67%.
The Revenue for XAIR have been decreasing by -31.56% on average. This is quite bad
EPS 1Y (TTM)31.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.1%
Revenue 1Y (TTM)680.67%
Revenue growth 3Y10.03%
Revenue growth 5Y-31.56%
Sales Q2Q%233.89%

3.2 Future

The Earnings Per Share is expected to grow by 20.75% on average over the next years. This is a very strong growth
XAIR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 208.93% yearly.
EPS Next Y56.62%
EPS Next 2Y30.41%
EPS Next 3Y20.75%
EPS Next 5YN/A
Revenue Next Year161.35%
Revenue Next 2Y209.09%
Revenue Next 3Y208.93%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XAIR. In the last year negative earnings were reported.
Also next year XAIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XAIR's earnings are expected to grow with 20.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.41%
EPS Next 3Y20.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XAIR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEYOND AIR INC

NASDAQ:XAIR (1/3/2025, 8:11:03 PM)

After market: 0.36 0 (0%)

0.36

+0 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)02-10 2025-02-10/amc
Inst Owners34.4%
Inst Owner Change24.25%
Ins Owners22.24%
Ins Owner Change23.82%
Market Cap25.99M
Analysts81.82
Price Target2.55 (608.33%)
Short Float %2.04%
Short Ratio1.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.98%
Min EPS beat(2)3.34%
Max EPS beat(2)16.63%
EPS beat(4)4
Avg EPS beat(4)13.33%
Min EPS beat(4)3.34%
Max EPS beat(4)25.85%
EPS beat(8)5
Avg EPS beat(8)1.24%
EPS beat(12)6
Avg EPS beat(12)-12.67%
EPS beat(16)7
Avg EPS beat(16)-12.56%
Revenue beat(2)0
Avg Revenue beat(2)-20.52%
Min Revenue beat(2)-24.93%
Max Revenue beat(2)-16.12%
Revenue beat(4)0
Avg Revenue beat(4)-23.33%
Min Revenue beat(4)-38.33%
Max Revenue beat(4)-13.95%
Revenue beat(8)0
Avg Revenue beat(8)-53.45%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)60.26%
EPS NY rev (1m)0%
EPS NY rev (3m)23.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-75.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-55.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.1
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-1.41
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0.03
BVpS0.39
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -104.67%
ROE -197.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.83%
ROA(5y)-72.3%
ROE(3y)-149.03%
ROE(5y)-127.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 256.79%
Cap/Sales 303.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.76
Quick Ratio 5.38
Altman-Z -9.11
F-Score6
WACC11.79%
ROIC/WACCN/A
Cap/Depr(3y)382.11%
Cap/Depr(5y)319.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.1%
EPS Next Y56.62%
EPS Next 2Y30.41%
EPS Next 3Y20.75%
EPS Next 5YN/A
Revenue 1Y (TTM)680.67%
Revenue growth 3Y10.03%
Revenue growth 5Y-31.56%
Sales Q2Q%233.89%
Revenue Next Year161.35%
Revenue Next 2Y209.09%
Revenue Next 3Y208.93%
Revenue Next 5YN/A
EBIT growth 1Y8.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.61%
EBIT Next 3Y47.01%
EBIT Next 5YN/A
FCF growth 1Y-71.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.71%
OCF growth 3YN/A
OCF growth 5YN/A